Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
|Videos|June 10, 2021
Upadacitinib for the Treatment of Atopic Dermatitis
Author(s)Morgan Petronelli
Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.
Advertisement
Advertisement
Related to this article
The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
Phase 2 SkinJect data support the 200-µg dose and inform Medicus’ FDA-authorized registrational program in Gorlin syndrome.
Advertisement
Advertisement
Trending on Dermatology Times
1
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
2
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
3
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
4
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
5